Fostamatinib Clinical Trials (2026): 62 Studies for Rheumatoid Arthritis & Pharmacokinetics
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
62 Fostamatinib clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 37 indications (including Rheumatoid Arthritis & Pharmacokinetics) and 10,078 total planned enrollment. 10 Phase 3 Fostamatinib trials and 22 Phase 2 are listed. 7 Fostamatinib clinical trials are actively recruiting at 3 U.S. sites across 3 states. Most recent activity: NCT06233110 (Jul 2029).
Where to Participate: All Fostamatinib Trial Sites in the U.S. (3 sites across 3 states)
Every actively recruiting Fostamatinibtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| CA | University of California, San Diego Moores Cancer Center | La Jolla92093 | NCT06639724 | Map |
| MD | National Institutes of Health Clinical Center | Bethesda20892 | NCT05904093 | Map |
| NC | Duke | Durham27710 | NCT06233110 | Map |
Fostamatinib clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | enrolling by invitation | completed | terminated | withdrawn | not yet recruiting | no longer available | Total |
|---|---|---|---|---|---|---|---|---|---|
| P1 | 3 | 16 | 1 | 20 | |||||
| P1/P2 | 1 | 2 | 3 | ||||||
| P2 | 11 | 7 | 3 | 1 | 22 | ||||
| P2/P3 | 1 | 1 | 2 | ||||||
| P3 | 1 | 8 | 1 | 10 | |||||
| N/A | 1 | 2 | 1 | 1 | 5 |
Recruiting Fostamatinib clinical trials (7)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT06233110 | Ruxolitinib Plus Fostamatinib for Steroid Refractory cGvHD | P1 | Chronic Graft Versus Host Disease | 30 | Oct 2025 |
| NCT06639724 | Perioperative Fostamatinib With Gemcitabine and Nab-paclitaxel in Resectable Pancreatic Cancer | P1 | Pancreatic Ductal Adenocarcinoma (PDAC) | 36 | Dec 2024 |
| NCT06757257 | Special Drug Use-results Survey for Long-term Use (Fostamatinib) | — | Chronic Idiopathic Thrombocytopenic Purpura | 149 | May 2023 |
| NCT06948097 | SIMILARSyk Inhibition in MItigating Lung Allograft Rejection (SIMILAR): A Trial to Evaluate the Safety and Tolerability of Fostamatinib in Lung Transplant Patients With Donor-Specific Antibodies | P1 | Lung Transplantation | 30 | Jun 2026 |
| NCT06564207 | FOSTA-ARDSFostamatinib for Treating Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Adults | P2 | Acute Respiratory Distress Syndrome | 40 | Aug 2026 |
| NCT05904093 | Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects With Stable Sickle Cell Disease | P1 | Sickle Cell Disease | 25 | Dec 2024 |
| NCT04138927 | A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia | P3 | Warm Antibody Autoimmune Hemolytic Anemia | 90 | Oct 2019 |
Fostamatinib clinical trials by indication
Rheumatoid Arthritis (17)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01242514 | OSKIRA-X | P3 | terminated | Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA) |
| NCT01264770 | OSKIRA -4 | P2 | terminated | Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA) |
| NCT00805467 | — | P2 | terminated | Open-Label, Multicenter Extension Study for Patients Completing Treatment Phase of a Rigel-Sponsored R935788 Studies |
| NCT01640054 | OSKIRA-Asia-1X | P2 | terminated | A Long Term Study to Assess the Safety of Fostamatinib in Patients in Asia With Rheumatoid Arthritis |
| NCT01569074 | OSKIRA-Asia-1 | P2 | terminated | Evaluation of Safety and Effectiveness of Fostamatinib Compared to Placebo in Patients in Asia With Rheumatoid Arthritis |
| NCT02092961 | OSKIRA 4 SS | P2 | terminated | Randomised Double-Blind, Placebo-Controlled, Parallel Group Study in Patients With Active Rheumatoid Arthritis:Magnetic Resonance Imaging Sub-Study |
| NCT01197534 | OSKIRA - 2 | P3 | completed | Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Disease Modifying Anti-rheumatic Drug (DMARD) But Not Responding. |
| NCT01197755 | OSKIRA - 3 | P3 | completed | Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist |
| + 9 more, see All trials below. | ||||
Immune Thrombocytopenic Purpura (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02077192 | ITP | P3 | completed | Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP) |
| NCT03363334 | — | N/A | no longer available | Expanded Access of Fostamatinib in Patients With Persistent or Chronic Relapsing/Refractory ITP |
| NCT02076412 | FIT | P3 | completed | A Efficacy and Safety Study of Fostamatinib in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP) |
| NCT02076399 | FIT | P3 | completed | A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP) |
Warm Antibody Autoimmune Hemolytic Anemia (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04138927 | — | P3 | enrolling by invitation | A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia |
| NCT03764618 | — | P3 | completed | A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of wAIHA |
| NCT02612558 | SOAR | P2 | completed | A Safety and Efficacy Study of R935788 in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (AIHA) |
Immune Mediated Anemia (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05509582 | — | P2 | withdrawn | Extension Study (Extended Access) of Syk-inhibition Using Fostamatinib to Treat Posttransplant Immune-mediated Cytopenias |
| NCT05502783 | — | P2 | terminated | Using Fostamatinib to Treat Post-Hematopoietic Stem Cell Transplant Immune-mediated Cytopenias |
COVID-19 (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04924660 | NECTAR | P2/P3 | completed | Novel Experimental COVID-19 Therapies Affecting Host Response |
| NCT05593770 | NECTAR | P2/P3 | terminated | International Sites: Novel Experimental COVID-19 Therapies Affecting Host Response |
IGA Nephropathy (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02112838 | — | P2 | completed | Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) Nephropathy |
| NCT02433236 | — | P2 | withdrawn | Open Label Study of Fostamatinib in the Treatment of IgA Nephropathy |
Healthy (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01598571 | — | P1 | completed | Study in Healthy Males to Assess Bioavailability of Single Fostamatinib With iv Micro Tracer Dose |
| NCT01387308 | — | P1 | completed | Study in Healthy Males to Assess the Bioavailability of 4 Different Fostamatinib Tablets |
Acute Respiratory Distress Syndrome (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06564207 | FOSTA-ARDS | P2 | not yet recruiting | Fostamatinib for Treating Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Adults |
Lung Transplantation (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06948097 | SIMILAR | P1 | not yet recruiting | Syk Inhibition in MItigating Lung Allograft Rejection (SIMILAR): A Trial to Evaluate the Safety and Tolerability of Fostamatinib in Lung Transplant Patients With Donor-Specific Antibodies |
Chronic Graft Versus Host Disease (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06233110 | — | P1 | recruiting | Ruxolitinib Plus Fostamatinib for Steroid Refractory cGvHD |
Sickle Cell Disease (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05904093 | — | P1 | recruiting | Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects With Stable Sickle Cell Disease |
Pancreatic Ductal Adenocarcinoma (PDAC) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06639724 | — | P1 | recruiting | Perioperative Fostamatinib With Gemcitabine and Nab-paclitaxel in Resectable Pancreatic Cancer |
Chronic Idiopathic Thrombocytopenic Purpura (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06757257 | — | N/A | recruiting | Special Drug Use-results Survey for Long-term Use (Fostamatinib) |
ITP - Immune Thrombocytopenia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05613296 | — | N/A | completed | Real World Evaluation of the Activity and Safety of Fostamatinib in Consecutive Adult Patients With ITP |
Primary Immune Thrombocytopenia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06071520 | — | N/A | completed | Andalusian Experience in the Use of Fostamatinib in Patients With ITP. FOSTASUR Study |
Hidradenitis Suppurativa (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05040698 | — | P2 | completed | Study of the Effect of Fostamatinib Upon Cutaneous Inflammation in the Setting of Hidradenitis Suppurativa |
Refractory Chronic Myelomonocytic Leukemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05030675 | — | P1 | completed | Fostamatinib for the Treatment of Lower-risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia Who Have Failed Therapy With Hypomethylating Agents |
ITP (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04904276 | ITP | N/A | terminated | Observational Study of Fostamatinib as Second Line Therapy in Adult Patients With Immune Thrombocytopenia (ITP) and Insufficient Response to a Prior Therapy |
Myelofibrosis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04543279 | — | P2 | terminated | Fostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis With Severe Thrombocytopenia |
Covid19 (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04629703 | — | P3 | completed | Double-Blind, Randomized, Placebo-Controlled, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects |
Coronavirus Disease 2019 (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04579393 | — | P2 | completed | Fostamatinib for Hospitalized Adults With COVID-19 |
Coronavirus (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04581954 | MATIS | P1/P2 | completed | Inflammatory Signal Inhibitors for COVID-19 (MATIS) |
Renal Transplant Rejection (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03991780 | FOSTAMR | P1/P2 | active not recruiting | Fostamatinib in the Treatment of Chronic Active Antibody Mediated Rejection |
Ovarian Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03246074 | — | P1 | completed | Clinical Trial of Combined Fostamatinib and Paclitaxel in Ovarian Cancer |
Hematological Malignancies (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02611063 | — | P1 | completed | Evaluation of Fostamatinib in Patients With cGVHD After Allogeneic Stem Cell Transplant |
Pharmacokinetics (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01682408 | PK Combination | P1 | completed | Assess Pharmacokinetics of Fostamatinib in Fed and Fasted State in Combination With Ranitidine to Assess Bioavailability |
Healthy Japanese Volunteers (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01608542 | — | P1 | completed | A Single and Multiple Dose Study to Assess Blood and Urine Drug Levels of Fostamatinib in Healthy Japanese Subjects |
Diffuse Large B-Cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01499303 | — | P2 | completed | Study to Learn if 200mg Test Drug (Fostamatinib) Helps People With Large B-Cell Lymphoma,a Type of Blood Cancer |
Healthy Volunteers (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01355354 | — | P1 | completed | Effects of Administration of Fostamatinib on Blood Concentrations of Digoxin in Healthy Subjects |
Scientific Terminology Rheumatoid Arthritis, Healthy Female Volunteers, Pharmacokinetics, Oral Contraceptive, Drug-drug Interaction (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01276262 | — | P1 | completed | Effects of Administration of Fostamatinib on Blood Concentrations of an Oral Contraceptive in Healthy Female Subjects |
Hepatic Impairment (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01222455 | — | P1 | completed | A Study of Fostamatinib in Subjects With Impaired Hepatic (Liver) Function |
Bioavailability (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01208155 | — | P1 | completed | Study in Healthy Males to Assess Bioavailability of 4 Different Fostamatinib Tablets |
Head and Neck Neoplasms (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00923481 | — | P2 | completed | A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H... |
T Cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00798096 | — | P2 | completed | Efficacy and Safety Study of Fostamatinib Disodium Tablets to Treat T-Cell Lymphoma |
Systemic Lupus Erythematosus (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00752999 | SOLEIL | P2 | withdrawn | Efficacy and Safety Study of R935788 Tablets to Treat Systemic Lupus Erythematosus |
Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00446095 | — | P1/P2 | completed | Efficacy and Safety Study of Fostamatinib Tablets to Treat B-cell Lymphoma |
Purpura, Thrombocytopenic, Idiopathic (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00706342 | ITP | P2 | completed | Pilot Study of Fostamatinib Disodium/R935788 for the Treatment of Adult Refractory Immune Thrombocytopenic Purpura (ITP) |
Fostamatinib pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| ITP | NCT02077192 | P3 | completed | Immune Thrombocytopenic Purpura | 123 | — |
| FIT | NCT02076412 | P3 | completed | Immune Thrombocytopenic Purpura | 74 | PMID 33995988 |
| FIT | NCT02076399 | P3 | completed | Immune Thrombocytopenic Purpura | 76 | — |
| OSKIRA-X | NCT01242514 | P3 | terminated | Rheumatoid Arthritis | 1,917 | — |
| OSKIRA - 2 | NCT01197534 | P3 | completed | Rheumatoid Arthritis | 913 | — |
| OSKIRA - 3 | NCT01197755 | P3 | completed | Rheumatoid Arthritis | 323 | — |
| OSKIRA - 1 | NCT01197521 | P3 | completed | Rheumatoid Arthritis | 923 | PMID 29669391 |
| FOSTA-ARDS | NCT06564207 | P2 | not yet recruiting | Acute Respiratory Distress Syndrome | 40 | — |
| SOAR | NCT02612558 | P2 | completed | Warm Antibody Autoimmune Hemolytic Anemia | 26 | PMID 35179251 |
| OSKIRA -4 | NCT01264770 | P2 | terminated | Rheumatoid Arthritis | 644 | PMID 25074688 |
| OSKIRA-Asia-1X | NCT01640054 | P2 | terminated | Rheumatoid Arthritis | 115 | PMID 33254235 |
| OSKIRA-Asia-1 | NCT01569074 | P2 | terminated | Rheumatoid Arthritis | 163 | — |
| OSKIRA 4 SS | NCT02092961 | P2 | terminated | Rheumatoid Arthritis | 198 | — |
| Oskira ABPM | NCT01563978 | P2 | completed | Rheumatoid Arthritis | 266 | — |
| ITP | NCT00706342 | P2 | completed | Purpura, Thrombocytopenic, Idiopathic | 18 | PMID 19096013 |
| SOLEIL | NCT00752999 | P2 | withdrawn | Systemic Lupus Erythematosus | 0 | — |
| Taski-3 | NCT00665626 | P2 | completed | Rheumatoid Arthritis | 219 | — |
| Taski-2 | NCT00665925 | P2 | completed | Rheumatoid Arthritis | 457 | PMID 20879879 |
Terminated and withdrawn Fostamatinib trials (13)
Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.
- NCT05509582withdrawnExtension Study (Extended Access) of Syk-inhibition Using Fostamatinib to Treat Posttransplant Immune-mediated Cytopenias
- NCT05593770terminatedInternational Sites: Novel Experimental COVID-19 Therapies Affecting Host Response
- NCT05502783terminatedUsing Fostamatinib to Treat Post-Hematopoietic Stem Cell Transplant Immune-mediated Cytopenias
- NCT04904276terminatedObservational Study of Fostamatinib as Second Line Therapy in Adult Patients With Immune Thrombocytopenia (ITP) and Insufficient Response to a Prior Therapy
- NCT04543279terminatedFostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis With Severe Thrombocytopenia
- NCT02433236withdrawnOpen Label Study of Fostamatinib in the Treatment of IgA Nephropathy
- NCT01242514terminatedEvaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
- NCT01264770terminatedEvaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)
- NCT00805467terminatedOpen-Label, Multicenter Extension Study for Patients Completing Treatment Phase of a Rigel-Sponsored R935788 Studies
- NCT01640054terminatedA Long Term Study to Assess the Safety of Fostamatinib in Patients in Asia With Rheumatoid Arthritis
- NCT01569074terminatedEvaluation of Safety and Effectiveness of Fostamatinib Compared to Placebo in Patients in Asia With Rheumatoid Arthritis
- NCT02092961terminatedRandomised Double-Blind, Placebo-Controlled, Parallel Group Study in Patients With Active Rheumatoid Arthritis:Magnetic Resonance Imaging Sub-Study
- NCT00752999withdrawnEfficacy and Safety Study of R935788 Tablets to Treat Systemic Lupus Erythematosus
All Fostamatinib trials (62)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT06233110 | Ruxolitinib Plus Fostamatinib for Steroid Refractory cGvHD | P1 | recruiting | 30 | Stefanie Sarantopoulos, MD, PhD. | Oct 2025 | |
| NCT06639724 | Perioperative Fostamatinib With Gemcitabine and Nab-paclitaxel in Resectable Pancreatic Cancer | P1 | recruiting | 36 | University of California, San Diego | Dec 2024 | |
| NCT06757257 | Special Drug Use-results Survey for Long-term Use (Fostamatinib) | — | recruiting | 149 | Kissei Pharmaceutical Co., Ltd. | May 2023 | |
| NCT06948097 | SIMILAR | Syk Inhibition in MItigating Lung Allograft Rejection (SIMILAR): A Trial to Evaluate the Safety and Tolerability of Fostamatinib in Lung Transplant Patients With Donor-Specific Antibodies | P1 | not yet recruiting | 30 | National Heart, Lung, and Blood Institute (NHLBI) | Jun 2026 |
| NCT06564207 | FOSTA-ARDS | Fostamatinib for Treating Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Adults | P2 | not yet recruiting | 40 | Inova Health Care Services | Aug 2026 |
| NCT05904093 | Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects With Stable Sickle Cell Disease | P1 | recruiting | 25 | National Heart, Lung, and Blood Institute (NHLBI) | Dec 2024 | |
| NCT05509582 | Extension Study (Extended Access) of Syk-inhibition Using Fostamatinib to Treat Posttransplant Immune-mediated Cytopenias | P2 | withdrawn | 0 | National Heart, Lung, and Blood Institute (NHLBI) | Nov 2025 | |
| NCT03991780 | FOSTAMR | Fostamatinib in the Treatment of Chronic Active Antibody Mediated Rejection | P1/P2 | active not recruiting | 8 | Imperial College London | May 2019 |
| NCT05030675 | Fostamatinib for the Treatment of Lower-risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia Who Have Failed Therapy With Hypomethylating Agents | P1 | completed | 11 | M.D. Anderson Cancer Center | Aug 2021 | |
| NCT05613296 | Real World Evaluation of the Activity and Safety of Fostamatinib in Consecutive Adult Patients With ITP | — | completed | 95 | Gruppo Italiano Malattie EMatologiche dell'Adulto | May 2023 | |
| NCT04138927 | A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia | P3 | enrolling by invitation | 90 | Rigel Pharmaceuticals | Oct 2019 | |
| NCT04924660 | NECTAR | Novel Experimental COVID-19 Therapies Affecting Host Response | P2/P3 | completed | 1,060 | Sean Collins | Jul 2021 |
| NCT05593770 | NECTAR | International Sites: Novel Experimental COVID-19 Therapies Affecting Host Response | P2/P3 | terminated | 28 | NEAT ID Foundation | Oct 2022 |
| NCT04581954 | MATIS | Inflammatory Signal Inhibitors for COVID-19 (MATIS) | P1/P2 | completed | 185 | Imperial College London | Oct 2020 |
| NCT06071520 | Andalusian Experience in the Use of Fostamatinib in Patients With ITP. FOSTASUR Study | — | completed | 50 | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | Mar 2023 | |
| NCT05502783 | Using Fostamatinib to Treat Post-Hematopoietic Stem Cell Transplant Immune-mediated Cytopenias | P2 | terminated | 1 | National Heart, Lung, and Blood Institute (NHLBI) | Mar 2023 | |
| NCT03246074 | Clinical Trial of Combined Fostamatinib and Paclitaxel in Ovarian Cancer | P1 | completed | 35 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Apr 2018 | |
| NCT05040698 | Study of the Effect of Fostamatinib Upon Cutaneous Inflammation in the Setting of Hidradenitis Suppurativa | P2 | completed | 20 | Holdsworth House Medical Practice | Oct 2021 | |
| NCT04904276 | ITP | Observational Study of Fostamatinib as Second Line Therapy in Adult Patients With Immune Thrombocytopenia (ITP) and Insufficient Response to a Prior Therapy | — | terminated | 16 | Rigel Pharmaceuticals | May 2021 |
| NCT04629703 | Double-Blind, Randomized, Placebo-Controlled, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects | P3 | completed | 280 | Rigel Pharmaceuticals | Mar 2021 | |
| NCT04543279 | Fostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis With Severe Thrombocytopenia | P2 | terminated | 3 | Washington University School of Medicine | May 2021 | |
| NCT03764618 | A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of wAIHA | P3 | completed | 90 | Rigel Pharmaceuticals | Apr 2019 | |
| NCT02611063 | Evaluation of Fostamatinib in Patients With cGVHD After Allogeneic Stem Cell Transplant | P1 | completed | 22 | Stefanie Sarantopoulos, MD, PhD. | Jan 2016 | |
| NCT04579393 | Fostamatinib for Hospitalized Adults With COVID-19 | P2 | completed | 59 | National Heart, Lung, and Blood Institute (NHLBI) | Oct 2020 | |
| NCT02077192 | ITP | Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP) | P3 | completed | 123 | Rigel Pharmaceuticals | Oct 2014 |
| NCT02612558 | SOAR | A Safety and Efficacy Study of R935788 in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (AIHA) | P2 | completed | 26 | Rigel Pharmaceuticals | Jul 2016 |
| NCT02112838 | Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) Nephropathy | P2 | completed | 76 | Rigel Pharmaceuticals | Oct 2014 | |
| NCT03363334 | Expanded Access of Fostamatinib in Patients With Persistent or Chronic Relapsing/Refractory ITP | — | no longer available | 0 | Rigel Pharmaceuticals | — | |
| NCT02076412 | FIT | A Efficacy and Safety Study of Fostamatinib in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP) | P3 | completed | 74 | Rigel Pharmaceuticals | Jan 2015 |
| NCT02076399 | FIT | A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP) | P3 | completed | 76 | Rigel Pharmaceuticals | Jul 2014 |
| NCT02433236 | Open Label Study of Fostamatinib in the Treatment of IgA Nephropathy | P2 | withdrawn | 0 | Rigel Pharmaceuticals | Sep 2015 | |
| NCT01242514 | OSKIRA-X | Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA) | P3 | terminated | 1,917 | AstraZeneca | Jan 2011 |
| NCT01499303 | Study to Learn if 200mg Test Drug (Fostamatinib) Helps People With Large B-Cell Lymphoma,a Type of Blood Cancer | P2 | completed | 101 | AstraZeneca | Dec 2011 | |
| NCT01264770 | OSKIRA -4 | Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA) | P2 | terminated | 644 | AstraZeneca | Jan 2011 |
| NCT00805467 | Open-Label, Multicenter Extension Study for Patients Completing Treatment Phase of a Rigel-Sponsored R935788 Studies | P2 | terminated | 624 | AstraZeneca | Aug 2008 | |
| NCT01640054 | OSKIRA-Asia-1X | A Long Term Study to Assess the Safety of Fostamatinib in Patients in Asia With Rheumatoid Arthritis | P2 | terminated | 115 | AstraZeneca | Jul 2012 |
| NCT01569074 | OSKIRA-Asia-1 | Evaluation of Safety and Effectiveness of Fostamatinib Compared to Placebo in Patients in Asia With Rheumatoid Arthritis | P2 | terminated | 163 | AstraZeneca | Apr 2012 |
| NCT02092961 | OSKIRA 4 SS | Randomised Double-Blind, Placebo-Controlled, Parallel Group Study in Patients With Active Rheumatoid Arthritis:Magnetic Resonance Imaging Sub-Study | P2 | terminated | 198 | AstraZeneca | Feb 2011 |
| NCT01197534 | OSKIRA - 2 | Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Disease Modifying Anti-rheumatic Drug (DMARD) But Not Responding. | P3 | completed | 913 | AstraZeneca | Sep 2010 |
| NCT01197755 | OSKIRA - 3 | Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist | P3 | completed | 323 | AstraZeneca | Sep 2010 |
| NCT01725230 | Statin DDI | Assess the Pharmacokinetics of Rosuvastatin and Simvastatin When Administered Alone or in Combination With Fostamatinib | P1 | completed | 42 | AstraZeneca | Nov 2012 |
| NCT01563978 | Oskira ABPM | Study of the Effect of Fostamatinib Twice Daily on Blood Pressure in Patients With Rheumatoid Arthritis | P2 | completed | 266 | AstraZeneca | Apr 2012 |
| NCT01682408 | PK Combination | Assess Pharmacokinetics of Fostamatinib in Fed and Fasted State in Combination With Ranitidine to Assess Bioavailability | P1 | completed | 28 | AstraZeneca | Sep 2012 |
| NCT01197521 | OSKIRA - 1 | Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Not Responding. | P3 | completed | 923 | AstraZeneca | Sep 2010 |
| NCT01608542 | A Single and Multiple Dose Study to Assess Blood and Urine Drug Levels of Fostamatinib in Healthy Japanese Subjects | P1 | completed | 24 | AstraZeneca | Jun 2012 | |
| NCT01598571 | Study in Healthy Males to Assess Bioavailability of Single Fostamatinib With iv Micro Tracer Dose | P1 | completed | 37 | AstraZeneca | May 2012 | |
| NCT00923481 | A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H... | P2 | completed | 37 | National Cancer Institute (NCI) | Apr 2009 | |
| NCT01276262 | Effects of Administration of Fostamatinib on Blood Concentrations of an Oral Contraceptive in Healthy Female Subjects | P1 | completed | 22 | AstraZeneca | Mar 2011 | |
| NCT01387308 | Study in Healthy Males to Assess the Bioavailability of 4 Different Fostamatinib Tablets | P1 | completed | 24 | AstraZeneca | Aug 2011 | |
| NCT01355354 | Effects of Administration of Fostamatinib on Blood Concentrations of Digoxin in Healthy Subjects | P1 | completed | 21 | AstraZeneca | Jun 2011 | |
| NCT01336218 | Effects of Administration of Fostamatinib on Blood Concentrations of Rifampicin in Healthy Subjects. | P1 | completed | 15 | AstraZeneca | Apr 2011 | |
| NCT01245790 | A Study of Fostamatinib in Subjects With Impaired Kidney Function | P1 | completed | 24 | AstraZeneca | Nov 2010 | |
| NCT01222455 | A Study of Fostamatinib in Subjects With Impaired Hepatic (Liver) Function | P1 | completed | 32 | AstraZeneca | Oct 2010 | |
| NCT01311622 | Effects of Administration of Fostamatinib on Blood Concentrations of Warfarin in Healthy Subjects | P1 | completed | 15 | AstraZeneca | Mar 2011 | |
| NCT01309854 | Effects of Administration of Fostamatinib on Blood Concentrations of Pioglitazone in Healthy Subjects | P1 | completed | 15 | AstraZeneca | Mar 2011 | |
| NCT01208155 | Study in Healthy Males to Assess Bioavailability of 4 Different Fostamatinib Tablets | P1 | completed | 24 | AstraZeneca | Sep 2010 | |
| NCT00446095 | Efficacy and Safety Study of Fostamatinib Tablets to Treat B-cell Lymphoma | P1/P2 | completed | 81 | Rigel Pharmaceuticals | Apr 2007 | |
| NCT00798096 | Efficacy and Safety Study of Fostamatinib Disodium Tablets to Treat T-Cell Lymphoma | P2 | completed | 18 | Rigel Pharmaceuticals | Mar 2009 | |
| NCT00706342 | ITP | Pilot Study of Fostamatinib Disodium/R935788 for the Treatment of Adult Refractory Immune Thrombocytopenic Purpura (ITP) | P2 | completed | 18 | Rigel Pharmaceuticals | Jan 2007 |
| NCT00752999 | SOLEIL | Efficacy and Safety Study of R935788 Tablets to Treat Systemic Lupus Erythematosus | P2 | withdrawn | 0 | Rigel Pharmaceuticals | Nov 2008 |
| NCT00665626 | Taski-3 | Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis (Taski-3) | P2 | completed | 219 | Rigel Pharmaceuticals | May 2008 |
| NCT00665925 | Taski-2 | Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis | P2 | completed | 457 | Rigel Pharmaceuticals | May 2008 |
Fostamatinib clinical trials: frequently asked questions
- How many Fostamatinib clinical trials are there?
- 62 Fostamatinib clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 5 are actively recruiting participants. 40 are marked completed.
- Are Fostamatinib clinical trials recruiting in 2026?
- Yes — 5 Fostamatinib trials are actively recruiting in 2026, with 3 U.S. sites across 3 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is Fostamatinib being studied for?
- Fostamatinib is being studied for Rheumatoid Arthritis, Pharmacokinetics, Healthy Volunteers, Immune Thrombocytopenic Purpura, Warm Antibody Autoimmune Hemolytic Anemia and 64 more. The trials are grouped by indication on this page.
- What phase is Fostamatinib in?
- Fostamatinib clinical trials span 10 Phase 3, 22 Phase 2, 20 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Fostamatinib clinical trials?
- The lead sponsor across the most Fostamatinib trials is AstraZeneca, with 16 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Fostamatinibas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: